Protein geranylgeranyltransferase type I (GGTase-I) is responsible for the posttranslational lipidation of CAAX proteins such as RHOA, RAC1, and cell division cycle 42 (CDC42). Inhibition of GGTase-I has been suggested as a strategy to treat cancer and a host of other diseases. Although several GGTase-I inhibitors (GGTIs) have been synthesized, they have very different properties, and the effects of GGTIs and GGTase-I deficiency are unclear. One concern is that inhibiting GGTase-I might lead to severe toxicity. In this study, we determined the effects of GGTase-I deficiency on cell viability and K-RAS-induced cancer development in mice. Inactivating the gene for the critical β subunit of GGTase-I eliminated GGTase-I activity, disrupted the actin cytoskeleton, reduced cell migration, and blocked the proliferation of fibroblasts expressing oncogenic K-RAS. Moreover, the absence of GGTase-I activity reduced lung tumor formation, eliminated myeloproliferative phenotypes, and increased survival of mice in which expression of oncogenic K-RAS was switched on in lung cells and myeloid cells. Interestingly, several cell types remained viable in the absence of GGTase-I, and myelopoiesis appeared to function normally. These findings suggest that inhibiting GGTase-I may be a useful strategy to treat K-RAS-induced malignancies.
Introduction
More than 100 intracellular proteins contain a CAAX motif that directs isoprenylation at a carboxyterminal cysteine (the "C" of the CAAX motif) (1) . Some CAAX proteins, such as RHOA, cell division cycle 42 (CDC42), and RAP1, are geranylgeranylated by protein geranylgeranyltransferase type I (GGTase-I). Others, such as K-RAS and N-RAS, are farnesylated by protein farnesyltransferase (FTase) (2) . If the "X" of the CAAX motif is a leucine, the protein is generally geranylgeranylated; otherwise, it is farnesylated (3). Isoprenylation renders the carboxyl terminus of the CAAX proteins more hydrophobic, enhancing their ability to bind to membranes within cells, and also regulates protein-protein interactions. GGTase-I and FTase share a common α subunit but have unique β subunits that dictate their substrate specificities (2) .
In some eukaryotic cells, GGTase-I is an essential enzyme. Null mutations in the β subunit of GGTase-I are lethal in both Drosophila melanogaster (4) and Saccharomyces cerevisiae (5) . The lethality of GGTase-I deficiency in S. cerevisiae was likely due to the failure to geranylgeranylate Rho1p and Cdc42p, as the lethality could be overcome by expressing mutant Rho1p and Cdc42p proteins engineered to undergo farnesylation by FTase (6) . Interestingly, Candida albicans and Arabidopsis thaliana are viable in the absence of GGTase-I (7, 8) . Remarkably, the impact of GGTase-I deficiency in mammalian cells has never been studied.
The realization that the RAS proteins are farnesylated (9) has fueled interest in protein isoprenylation. Farnesylation is important for the proper membrane targeting of RAS proteins and for their transforming ability (10) . In mouse models, farnesyltransferase inhibitors (FTIs) have significant antitumor activity and minimal toxicity (11) . In human clinical trials, however, FTIs have been disappointing, at least for the treatment of solid tumors (12) , likely because K-RAS and N-RAS -the RAS isoforms most often implicated in human cancer -can be geranylgeranylated in the presence of an FTI (13) .
The realization that K-RAS and N-RAS can be geranylgeranylated in the setting of FTI therapy prompted efforts to develop GGTase-I inhibitors (GGTIs). GGTIs could be used in combination with FTIs to block the isoprenylation of K-RAS and N-RAS. The rationale for using GGTIs in cancer therapy is further underscored by the fact that geranylgeranylated proteins, such as RHOA, RHOC, and RALA, are intimately involved in tumor development and metastasis (14) (15) (16) . Several GGTIs inhibit the growth of tumor cell lines, including cell lines with K-RAS mutations (17) (18) (19) . Interest in developing GGTIs actually extends beyond cancer therapy (20) . Inhibition of GGTase-I ameliorated disease phenotypes in a mouse model of multiple sclerosis (21) and inhibited hepatitis C viral replication in hepatoma cells (22) . Also, inhibiting GGTase-I in C. albicans is being evaluated as a strategy to treat nosocomial infections (23) .
Despite indications that inhibiting GGTase-I might be useful therapeutically, there is concern regarding the potential toxicity of this approach, in part because geranylgeranylated proteins are more numerous than farnesylated proteins (1). Another reason for concern is that GGTIs have been shown to induce apoptosis of cultured cells and cause toxicity in mouse models (24) (25) (26) . Other studies, however, have suggested that some GGTIs might not be particularly toxic (27, 28) .
We reasoned that our understanding of the physiologic importance of protein geranylgeranylation could be improved substantially with genetic studies in mice. In this study, we created mice with a conditional knockout allele for the β subunit of GGTase-I (Pggt1b fl mice) and defined the impact of Pggt1b deficiency on cell viability, cell proliferation, and K-RAS-induced oncogenic transformation.
Results

Generation and validation of a conditional GGTase-I knockout allele.
The strategy for creating Pggt1b fl mice is illustrated in Figure 1A . In the mutant allele (Pggt1b fl ), loxP sites flank exon 7, which is critical for enzymatic activity (29) . Pggt1b fl/+ and Pggt1b fl/fl mice were healthy and fertile. To test the conditional allele, we treated Pggt1b fl/fl embryonic fibroblasts with a Cre-adenovirus. Cre recombination converted the Pggt1b fl allele to a null allele (Pggt1b Δ ), which produced a transcript lacking exon 7 (which yields a frameshift) ( Figure 1B ). As expected, inactivation of Pggt1b eliminated GGTase-I activity but did not affect FTase activity ( Figure 1C ). In heterozygous knockout cells (Pggt1b Δ/+ ), GGTase-I activity was reduced by approximately 50% (data not shown).
To assess the impact of Pggt1b deficiency on the processing of 2 GGTase-I substrates, RAP1 and RHOA, we subjected fibroblast extracts to Western blot analysis with an antibody specific for nonprenylated RAP1. Nonprenylated RAP1 accumulated in both the soluble and membrane fractions of the Pggt1b Δ/Δ cells (Figure 1 , D and E). Western blots with an antibody recognizing total RAP1 revealed that RAP1 had a slower electrophoretic mobility in Pggt1b Δ/Δ cells ( Figure 1, D and E) . The inactivation of Pggt1b also resulted in a 2-to 4-fold accumulation of RHOA within cells ( Figure 1D ).
Pggt1b deficiency blocks proliferation and migration of normal fibroblasts and K-RAS G12D -expressing fibroblasts but does not affect cell viability.
Inactivating a single Pggt1b allele in Pggt1b fl/+ fibroblasts did not affect cell proliferation (Figure 2A ). Inactivating both alleles in Pggt1b fl/fl cells arrested proliferation (Figure 2A ) but had little or no effect on cell viability, as the cells remained viable for more than 3 weeks after the Cre-adenovirus treatment. The proliferation arrest in Pggt1b Δ/Δ cells appeared to be irreversible, as we were unable to generate stable Pggt1b Δ/Δ cell lines. In contrast, we had no difficulty isolating Pggt1b Δ/+ fibroblast cell lines from littermate embryos. The Pggt1b Δ/Δ cells were small and spindle shaped, and the amount of polymerized actin was dramatically reduced ( Figure 2B ). To determine whether the reduced levels of polymerized actin in Pggt1b Δ/Δ cells impaired cellular migration, we performed a standard wound closure assay in cultured cells. The ability of Pggt1b Δ/Δ cells to migrate was reduced by 60%-80% ( Figure 2C ). Also, Western blots revealed increased levels of p21 CIP1 and phosphorylated AKT Ser473 and decreased levels of phosphorylated ERK1/2 in Pggt1b Δ/Δ cells than in the parental Pggt1b fl/fl cells ( Figure 2D ).
To assess the effect of Pggt1b deficiency on K-RAS-induced cell transformation, we generated primary fibroblasts from but not apoptosis or cell death. Inactivation of Pggt1b also prevented the K-RAS G12D -induced increase in cyclin D1 and resulted in increased levels of phosphorylated AKT but did not affect p21 CIP1 levels ( Figure 2D ). The proliferation arrest in Cre-adenovirus-treated Pggt1b fl/fl K LSL cells was associated with an increased fraction of cells in the G 1 phase of the cell cycle ( Figure 2G) .
Farnesylation of RHOA and CDC42 prevents cell rounding and temporarily restores proliferation of Pggt1b-deficient fibroblasts expressing K-RAS G12D . In S. cerevisiae, expression of farnesylated versions of RHOA and CDC42 (fRHOA and fCDC42, respectively) overcame the lethality associated with a deficiency of the yeast ortholog of Pggt1b (also known as CAL1) (6) . Accordingly, we hypothesized that fRHOA and fCDC42 might overcome the proliferation arrest in Cre-adenovirus-treated Pggt1b fl/fl K LSL cells. To test this hypothesis, we transfected primary Pggt1b fl/fl K LSL fibroblasts with plasmids encoding fRHOA (Myc-tagged at the amino terminus), fCDC42 (HA-tagged), or both and treated the cells with Creadenovirus. Both fRHOA and fCDC42 were expressed in transiently transfected cells ( Figure 3A ). The expression of fRHOA and fCDC42 (but neither construct alone) allowed Pggt1b Δ/Δ K G12D cells to escape, at least temporarily, the proliferation arrest and form colonies (Figure 3 , B and C). Treatment of the colonies with an FTI promptly induced cell rounding and proliferation arrest (compare Figure 3C with the lower-right panel in Figure 2F ). However, even in the absence of an FTI, Pggt1b Δ/Δ K G12D colonies eventually stopped growing and could not be developed into stable cell lines, presumably because the farnesylation of these proteins was inadequate for growth or because other GGTase-I substrates are also important for cell growth.
Myeloid cells are viable in the absence of Pggt1b. To further explore the effects of Pggt1b deficiency in mammalian cells, we bred Pggt1b fl/fl mice with lysozyme M-Cre-transgenic mice (LC mice; mice expressing Cre under the control of a myeloid-specific lysozyme M promoter [ref. 31] ). Pggt1b fl/+ LC and Pggt1b fl/fl LC mice were healthy and fertile, with normal white blood cell counts and normal histology of the spleen, liver, and bone marrow.
To determine the efficiency of Cre-induced inactivation of Pggt1b, we used quantitative PCR analysis of genomic DNA and cDNA. In bone marrow-derived, in vitro-differentiated macrophages from Pggt1b fl/fl LC mice, the efficiency of Cre recombination was 90% (genomic DNA, 90% ± 2.8%; cDNA, 90% ± 3.1%, n = 2). In unsorted thioglycollate-elicited peritoneal macrophages, the efficiency was somewhat lower (77%-89%). The yield of macrophages from different groups of mice did not differ, and more than 90% of monolayer cells were positive for the macrophage cell surface markers galectin-3 (MAC-2) and sialoadhesin (MAC-3), as judged by immunofluorescence microscopy. In genomic DNA from circulating white blood cells of Pggt1b fl/fl LC mice, the extent of Cre recombination was 20% ± 2.8% (n = 3). The mean percentage of myeloid cells in blood of the same mice was 25% ± 0.5%, suggesting approximately 80% efficiency of Cre recombination in circulating myeloid cells.
A knockout of Pggt1b ameliorates phenotypes and extends the lifespan of mice expressing K-RAS G12D . To determine the effect of inactivating Pggt1b during K-RAS-induced transformation in vivo, we produced mice that were heterozygous for the K LSL allele (30) and the LC allele (31) on a background of the conditional Pggt1b allele ( Figure 4A ). Because LC mice have primarily been used in studies of conditional allele inactivation in myeloid cells (32) (33) (34) , we suspected that K LSL LC mice would develop a K-RAS G12D -induced myeloid malignancy. However, lysozyme M is also known to be expressed in type II pneumocytes in the lung (35, 36) . Indeed, the dominant phenotype of the K LSL LC mice was lung cancer (described further below).
The K G12D allele in K LSL LC mice was activated in bone marrow and spleen, as expected, but it was also activated in lung ( Figure 4B ). The phenotypes of Pggt1b +/+ K LSL LC and Pggt1b fl/+ K LSL LC mice were indistinguishable from each other. Both appeared normal until they were 17 days old. At that point, however, their health deteriorated rapidly, and more than 95% of the mice died or had to be euthanized due to severe dyspnea and reduced body weight (median survival, day 20; maximum survival, day 24 and day 35, respectively) ( Figure 4C ). Although K-RAS G12D was expressed in myeloid cells, white blood cell counts were not increased in the Pggt1b fl/+ K LSL LC mice ( Figure 4D) ; however, the percentage of neutrophils in the peripheral blood was higher and the percentage of lymphocytes was lower than in littermate controls lacking the K LSL and LC alleles ( Figure 4E ). The most striking phenotype of the Pggt1b fl/+ K LSL LC mice was a 10-fold increase in lung weight at days 18-22 ( Figure 4F ) that resulted from lung tumors (see below). The survival of mice was monitored for 14 weeks; on day 98, all surviving mice were euthanized. Pggt1b fl/fl K LSL LC mice (K LSL LC mice that were homozygous for the Pggt1b conditional allele) survived far longer than Pggt1b fl/+ K LSL LC mice, some for the entire 98 days ( Figure 4C ; P < 0.0001). Pggt1b fl/fl K LSL LC mice gained weight at the same rate as control mice until day 40 and then grew more slowly ( Figure 4G ). At days 18-22, the percentages of neutrophils and lymphocytes in Pggt1b fl/fl K LSL LC mice were entirely normal ( Figure 4E) , and the white blood cell counts remained low throughout the experiment. The lung weight was lower in Pggt1b fl/fl K LSL LC than in Pggt1b fl/+ K LSL LC mice but was still higher than in control mice ( Figure 4F) .
Inactivation of Pggt1b delays the onset and reduces severity of K-RASinduced lung cancer.
The Pggt1b fl/+ K LSL LC mice developed lung tumors that ranged from atypical adenomatous hyperplasia (AAH), adenoma, and adenocarcinoma at day 11 ( Figure 5A ) to a diffuse adenocarcinoma that obliterated alveolar spaces by day 20 ( Figure 5B), undoubtedly explaining the dyspnea and premature death. In contrast, the Pggt1b fl/fl K LSL LC mice exhibited normal lung histology with only very mild AAH at day 11. At day 20 ( Figure 5 , C and D) and day 62, the lungs of Pggt1b fl/fl K LSL LC mice contained a few AAH lesions, but many segments of the lungs retained entirely normal histology. By day 98, the AAH had progressed and scattered adenomas were evident ( Figure 5, E and F) . Lung histology in the control mice is shown in Figure 5 Figure 5L) . Moreover, the levels of nonprenylated RAP1 were Figure 5L and data not shown). These data strongly suggest that lung tumors in Pggt1b fl/fl K LSL LC mice arose from cells that accumulate nonprenylated RAP1 (i.e., cells in which both Pggt1b alleles had been inactivated). G12D -expressing hematopoietic cells. Spleens from Pggt1b fl/+ K LSL LC mice contained an increased proportion of GR-1 + , CD11b + , and CD117 + cells, consistent with expansion of a pool of immature myeloid cells ( Figure 7A ). We hypothesized that these splenocytes would grow autonomously in vitro. Indeed, splenocytes from Pggt1b fl/+ K LSL LC mice formed colonies in the absence of growth factors, whereas splenocytes from control and Pggt1b fl/fl K LSL LC mice did not ( Figure 7B ). Similar results were obtained with bone marrow cells ( Figure 7C ). In the presence of growth factors (SCF, IL-3, IL-6, erythropoietin), bone marrow cells from Pggt1b fl/+ K LSL LC, Pggt1b fl/fl K LSL LC, and control mice formed similar numbers of colonies ( Figure 7D ). However, there were more GM-CFUs in the bone marrow of Pggt1b fl/+ K LSL LC mice than in Pggt1b fl/fl K LSL LC or control mice ( Figure 7D ; P < 0.01). Genotyping of the GM-CFU colonies shown in Figure 7D demonstrated that the K LSL allele was activated and that both Pggt1b alleles were inactivated ( Figure 7E ).
Inactivation of Pggt1b inhibits proliferation and colony growth of K-RAS
Discussion
In this study, we created mice with a conditional Pggt1b knockout allele and show that the inactivation of Pggt1b arrested proliferation and reduced migration of cultured fibroblasts; it also improved survival and reduced lung tumor formation and myeloproliferation in K LSL LC mice. Moreover, several cell types were viable in the absence of Pggt1b, including fibroblasts, macrophages, lung tumor cells, and cells within GM-CFU colonies.
In normal fibroblasts, inactivation of Pggt1b arrested proliferation, disrupted the actin cytoskeleton, increased the levels of p21 CIP1 , and reduced cell migration. In fibroblasts expressing K-RAS G12D , the absence of Pggt1b did not increase p21 CIP1 levels and resulted in cell rounding. A potential mechanism behind the cytoskeletal disruption and proliferation arrest in Pggt1b-deficient cells is inhibition of geranylgeranylation of the RHO family proteins such as RHOA and CDC42. In keeping with this idea, expressing fRHOA and fCDC42 prevented cell rounding in Pggt1b-deficient K-RAS G12D -expressing fibroblasts. However, the fRHOA and fCDC42 did not fully restore cell proliferation, suggesting that additional GGTase-I substrates are required for normal levels of cell proliferation.
The inactivation of Pggt1b significantly reduced lung tumor growth and improved survival in K LSL LC mice. However, tumors eventually developed in the Pggt1b fl/fl K LSL LC mice. Theoretically, these tumors might have arisen from K-RAS G12D -expressing cells in which Pggt1b was not completely inactivated. In fact, such a scenario was recently proposed to explain the results of experiments designed to assess the impact of Rac1 deficiency on K-RAS-induced lung cancer (37) . However, in the current study, we provide strong evidence that both alleles of Pggt1b were inactivated in lung tumor cells expressing K-RAS G12D .
The finding that both alleles of Pggt1b were inactivated in K-RAS G12D -expressing lung tumors suggests that mammalian cells can proliferate in the absence of GGTase-I activity. This notion is further supported by the finding that both Pggt1b alleles were inactivated in individual GM-CFU colonies from bone marrow of Pggt1b fl/fl K LSL LC mice. Why would the tumor cells and bone marrow cells be different from the cultured fibroblasts, which never proliferated in the absence of GGTase-I? One possibility is that the tumor cells accumulated additional mutations that allowed them to overcome the effect of Pggt1b deficiency. Another possibility is that alternate prenylation of key substrates by FTase was somehow more efficient in Pggt1b-deficient tumor cells. Some CAAX proteins, such as RHOB, KRAS, and NRAS, can be prenylated by both FTase and GGTase-I (38, 39) . Perhaps the tumor cells, but not the fibroblasts, eventually accumulated sufficient amounts of farnesylated proteins to permit cell growth.
In addition to lung cancer, activation of the K LSL allele by the LC allele resulted in a myeloproliferative phenotype, with infiltration of leukocytes in the liver and growth factor-independent colony growth of hematopoietic cells. Both of those phenotypes were eliminated in the absence of GGTase-I in Pggt1b fl/fl K LSL LC mice, and the white blood cell counts in the Pggt1b fl/fl K LSL LC mice remained low for the entire length of their lifespan (up to 98 days). In the future, it would be interesting to define the impact of GGTase-I deficiency on other experimental myeloproliferative disease syndromes, for example the one elicited when the K LSL allele is activated by the Mx1-Cre transgene (40, 41) .
In a recent study, inactivating the β subunit of FTase (Fntb) did not alter the development of K-RAS-induced lung cancer and had only a minor effect on H-RAS-induced skin cancer (42) . Also, Fntbdeficient fibroblasts grew in cell culture, albeit at a reduced rate. The current study indicates that GGTase-I deficiency has a greater impact than FTase deficiency on cell proliferation, migration, and K-RAS-induced transformation. Multiple factors likely contribute to this difference. One is that there are simply more geranylgeranylated than farnesylated proteins in cells (1) . It is also possible that the lipid modification is more important for geranylgeranylated proteins. A geranylgeranyl lipid is significantly more hydrophobic than a farnesyl lipid (43) , so it seems plausible that the loss of protein geranylgeranylation could have a greater effect on the avidity of proteins for membrane surfaces, and hence greater functional consequences, than loss of protein farnesylation.
The conditional Pggt1b allele we developed will make it feasible to compare the impact of genetic and pharmacologic inhibition of GGTase-I. Such studies could be enlightening because they might help to sort out mechanism-related versus compoundrelated effects of different GGTIs. Previously, GGTIs were reported to upregulate p21 CIP1 and induce apoptosis in cultured cells (27, 28, 44, 45) . However, in the current study, p21 CIP1 levels were not increased in K-RAS G12D -expressing Pggt1b-deficient cells. The explanation for this difference is not known. However, now that a genetic model of GGTase-I deficiency is in hand, it should be possible to define which effects of GGTIs are due to inhibition of GGTase-I and which are likely to be due to off-target effects of the GGTI. 
